Ivor Elrifi
Known title: Chief Executive OfficerCIK: 0002136241
Ivor Elrifi's purchase track record
Ivor Elrifi has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/3/2026 | TLSA | $986K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TLSA | ▲ Buy | Option Exercise | 1,050,000 | — | 8/15/2026 | View on chart |
| TLSA | ▲ Buy | Open Market | 237,616 | $238K | 8/5/2026 | View on chart |
| TLSA | ▲ Buy | Open Market | 83,807 | $81K | 8/4/2026 | View on chart |
| TLSA | ▲ Buy | Open Market | 667,000 | $667K | 8/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TLSA Doses First ALS Patients, Completes MS Trial Visits
Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.
TLSA Doses First ALS Patients, Completes MS Trial Visits. Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.